Document Detail

How to optimize HCV therapy in genotype 1 patients with cirrhosis.
MedLine Citation:
PMID:  23286846     Owner:  NLM     Status:  In-Data-Review    
Of all hepatitis C virus patients, those with cirrhosis are most in need of treatment owing to increased morbidity and mortality. Treatment with pegylated interferon and ribavirin (PEG-IFN/RBV) has clearly shown the benefits of successful treatment by improving fibrosis, causing the regression of cirrhosis and reducing and preventing cirrhosis-related complications. However, the sustained virological response (SVR) is lower in patients with cirrhosis. First generation protease inhibitors (boceprevir and telaprevir) in combination with PEG-IFN/RBV are a major advancement in the treatment of both naïve and treatment-experienced genotype 1 patients. In naïve patients, the SVR rate with the triple regimen with boceprevir increased by 14% in patients with severe fibrosis or cirrhosis compared to PEG-IFN/RBV compared by 30% in patients with mild or moderate fibrosis. The SVR rate of the triple regimen with telaprevir increased by 10-30% compared to PEG-IFN/RBV in patients with severe fibrosis or cirrhosis and by nearly 30% in patients with mild or moderate fibrosis. The greatest benefits seem to be found in patients with cirrhosis who have relapsed, and is limited in prior non-responder patients. Thus, the choice of triple therapy in the latter should be considered in relation to the increase in side effects. There are no data on the efficacy of the triple regimen in patients with decompensated cirrhosis. Results in real-life settings show that patients with cirrhosis need to be carefully followed-up during treatment due to the increase in side effects that are greater than in clinical studies. Next generation DAAs and PEG-IFN/RBV appear to be more effective and have fewer side effects in patients with cirrhosis. Ultimately, an interferon-free regimen of DAAs combinations will probably provide a SVR in patients with cirrhosis and will probably be proposed in patients with more advanced or decompensated cirrhosis.
Marc Bourlière; Astrid Wendt; Hélène Fontaine; Christophe Hézode; Stanislas Pol; Jean Pierre Bronowicki
Related Documents :
2075856 - Prevalence of bulimia among patients in a chemical dependency treatment program.
22388016 - Management of delayed postpolypectomy bleeding: a decision analysis.
1523236 - The single-item meal as a measure of binge-eating behavior in patients with bulimia ner...
22879706 - Characteristics of androgenetic alopecia in asian.
10426146 - Intracranial dural arteriovenous fistula (davf) presenting progressive dementia and par...
3594306 - Systemic illnesses in cataract patients: 2. prevalence.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  46-55     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Department of Hepato-Gastroenterology Hospital Saint Joseph, Marseille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How to optimize HCV therapy in genotype 4 patients.
Next Document:  Current management and perspectives for HCV recurrence after liver transplantation.